Document is current
Any future updates will be listed below
-
Authors
Moore, Stephen T.
Lian, Xizhen
Vaidya, Amogh https://orcid.org/0000-0003-0712-659X
Chatterjee, Sumanta
Santelli, Julien
Sun, Yehui https://orcid.org/0000-0003-0215-6095
Farbiak, Lukas https://orcid.org/0000-0003-4107-1676
Zhu, Hao https://orcid.org/0000-0002-8417-9698
Siegwart, Daniel J. https://orcid.org/0000-0003-3823-1931
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA142543)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (5R01EB025192-06)
- License Information
-
More Information
Article History
Received: 12 February 2025
Accepted: 17 December 2025
First Online: 7 January 2026
Competing interests
: The authors acknowledge competing interests in ReCode Therapeutics (D.J.S.), Signify Bio (D.J.S. and L.F.), Newlimit (H.Z.), Chroma Therapeutics (H.Z.), Quotient Therapeutics (H.Z.), and Jumble Therapeutics (D.J.S. and H.Z.). The remaining authors declare no competing interests.
